Janssen Research and Development LLC, The Pharmaceutical Companies of Johnson & Johnson, 200 Tournament Drive, Horsham, PA, 19044, USA.
BMS, New York, USA.
Ther Innov Regul Sci. 2024 Nov;58(6):1014-1022. doi: 10.1007/s43441-024-00694-7. Epub 2024 Sep 6.
The expanding availability of real-world data (RWD) has led to an increase in both the interest and possibilities for using this information in postmarketing safety analyses and signal management. While there is enormous potential value from the safety insights generated through RWD, the analysis preparation, execution, and communication required to reliably deliver the evidence can be time consuming. Since the safety signal assessment process is a regulated and timebound process, any supporting RWD analyses require a rapid turnaround of well-designed and informative results. To address this challenge, a TransCelerate BioPharma working group was formed and developed a framework to help teams responsible for safety signal assessment overcome the challenges of working with RWD rapidly to deliver analyses within regulatory timelines. Here, a previously performed safety assessment was evaluated within the context of the developed framework to illustrate how the framework may be adopted in practice.
真实世界数据(RWD)的可用性不断扩大,使得利用这些信息进行上市后安全性分析和信号管理的兴趣和可能性都有所增加。虽然从 RWD 中产生的安全性见解具有巨大的潜在价值,但为了可靠地提供证据,所需的分析准备、执行和沟通可能会很耗时。由于安全性信号评估过程是一个受监管且限时的过程,因此任何支持性的 RWD 分析都需要快速提供精心设计且有信息价值的结果。为了应对这一挑战,一个 TransCelerate 生物制药工作组成立了,并制定了一个框架,帮助负责安全性信号评估的团队克服在监管时间内快速使用 RWD 开展分析的挑战。在此,根据所制定的框架对之前进行的安全性评估进行了评估,以说明如何在实践中采用该框架。